The bullish ratings from analysts indicate a positive sentiment towards EyePoint Pharmaceuticals, which could potentially drive the stock price up. However, the decrease in the average price target suggests that analysts are less optimistic about the company's future performance than they were previously, which could potentially have a negative impact on the stock price.